Kevetrin, our lead product candidate, is a small molecule compound proprietary to the Company. Its structure is distinct from other anti-cancer agents currently on the market. While we are initially planning to develop Kevetrin to treat head and neck cancers, there is a potential for its use in multiple epithelial tumors. Kevetrin was discovered by the Company�s founder, Dr. Krishna Menon and has been studied extensively demonstrating potent anti-cancer activity against various cancer cell lines in both in vitro and in vivo studies. Kevetrin has been shown to be primarily an AKT inhibitor but also acts as an alkylating agent and LTB4 inhibitor with anti-angiogenic properties. Some of the highlights of the data we have compiled to date:
- Small molecule drug that is structurally different from anti-cancer agents currently on the market
- Primary mechanism of action is AKT inhibition
- Potent in vitro cytotoxicity against a panel of human tumor cell lines
- Demonstrated success in more than 5,000 small animal tests, achieving significant delays in tumor growth compared to controls in breast, prostate and colon cancer tumors.
- In animal tests of a head and neck cancer cell line, delay in tumor growth was significantly increased by 13 days with Kevetrin alone (about the same as with radiation alone) but when Kevetrin was administered in conjunction with radiation, tumor growth delay increased by 37 days, more than two-fold compared to controls
- In small animal tests, Kevetrin was well tolerated.
|
Home 
Sitemap
Contact Us
